Luyan Pharmaceutical released its 2026 semi-annual report. In the first half, net profit attributable to shareholders was about 143 million yuan, down 7.46% year-on-year. During the same period, the company achieved operating revenue of about 10.583 billion yuan, up 1.75% year-on-year. Luyan Pharmaceutical is mainly engaged in the distribution of pharmaceuticals, Chinese herbal medicine pieces, medical devices and other products, as well as retail pharmacy chain operations, with pharmaceutical wholesale being the main source of the company's revenue.
Luyan Pharma Co LtdNet profit attributable to shareholders fell 7.46% year-on-year in H1 2026.
